Dalton Pharma Services has announced the signing of a drug development and manufacturing services agreement with Cerium Pharmaceuticals, Inc., an emerging biopharmaceutical company based in Gaithersburg, Maryland, USA. Cerium is dedicated to the development and commercialization of medicines for patients with rare (orphan) diseases.
In support of Cerium’s drug development program, Dalton Pharma Services will provide formulation development, cGMP liquid filling, analytical method validation, quality control release testing and ICH stability services.
"Our expert capabilities in formulation development and sterile fill/finish of APIs combined with our strength in cGMP API manufacturing has led to the signing of this important drug development and manufacturing agreement," said Peter Pekos, President and CEO. “We are excited to have this opportunity and look forward to participating in Cerium’s drug development program, which has great promise for providing a therapy for a major unmet medical need.”
Gregg Lapointe, CEO of Cerium remarked, “Dalton is an excellent fit for our needs, and we are delighted to be partnering with a company whose client focus and commitment to quality match our own. Cerium will benefit greatly from having Dalton’s facilities, experience, technical expertise and array of integrated services to move our drug from R&D to cGMP manufacturing.”
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.